[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598002":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":24,"responsibleParty":43,"collaborators":45,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":115,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":127,"studyType":128,"phases":10,"briefSummary":129,"conditions":130,"keywords":133,"overallStatus":142,"whyStopped":10,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"Azienda Ospedaliera Universitaria Integrata Verona","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients who experienced tumor rupture during robotic partial nephrectomy",null,"Patients who experienced tumor rupture during RAPN (referred to an unintended breach of the tumor capsule with or without spillage of malignant tissue during tumor resection)",[13],"Procedure: robot-assisted partial nephrectomy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","robot-assisted partial nephrectomy","Robotic-Assisted Partial Nephrectomy (RAPN) is a minimally invasive surgical procedure performed with the help of a robotic system to remove a kidney tumor while preserving as much healthy kidney tissue as possible. It is commonly used to treat small to medium-sized kidney tumors. Thanks to the precision of robotic technology, RAPN offers faster recovery, less postoperative pain, and fewer complications compared to traditional open surgery.",[9],[21,22,23],"robotic partial nephrectomy","RAPN","RPN",[25],{"facility":26,"status":10,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"AOUI Verona","Verona","37120","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],10.9938,45.43854,{"lat":35,"lon":34},[38],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Riccardo Giuseppe Bertolo, MD, PhD","CONTACT","+39 045 812 1111","riccardogiuseppe.bertolo@univr.it",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[46,49,51,53,55,57,59,61,63,65,67,69,71,73,75,77,79,81,83,85,87,89,91,93,95,97,99,101,103,105,107,109,111],{"name":47,"class":48},"Fundación Investigación Hospital IMED Valencia, Valencia, Spain","UNKNOWN",{"name":50,"class":6},"Hospital Clinic of Barcelona",{"name":52,"class":6},"The Cleveland Clinic",{"name":54,"class":6},"Fundacio Puigvert",{"name":56,"class":6},"San Raffaele University Hospital, Italy",{"name":58,"class":6},"Guy's and St Thomas' NHS Foundation Trust",{"name":60,"class":6},"University Hospital, Bordeaux",{"name":62,"class":6},"Fox Chase Cancer Center",{"name":64,"class":6},"ASST Grande Ospedale Metropolitano Niguarda",{"name":66,"class":6},"Azienda Ospedaliero-Universitaria Careggi",{"name":68,"class":48},"Ospedale San Luigi Gonzaga, Orbassano",{"name":70,"class":48},"Changhai hospital of Navy Medical University",{"name":72,"class":6},"St. George's Hospital, London",{"name":74,"class":48},"Frimley Health NHS Foundation Trust",{"name":76,"class":6},"Icahn School of Medicine at Mount Sinai",{"name":78,"class":6},"Rennes University Hospital",{"name":80,"class":6},"University of Illinois at Chicago",{"name":82,"class":6},"University of California, San Diego",{"name":84,"class":48},"Hospital da Luz Lisboa, Portugal",{"name":86,"class":6},"Swedish Medical Center",{"name":88,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"name":90,"class":6},"St. Antonius Hospital Gronau",{"name":92,"class":6},"Regina Elena Cancer Institute",{"name":94,"class":6},"Pitié-Salpêtrière Hospital",{"name":96,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"name":98,"class":6},"Onze Lieve Vrouwziekenhuis Aalst",{"name":100,"class":6},"Hannover Medical School",{"name":102,"class":6},"Royal Free and University College Medical School",{"name":104,"class":6},"Università degli Studi del Piemonte Orientale Amedeo Avogadro",{"name":106,"class":6},"Memorial Sloan Kettering Cancer Center",{"name":108,"class":6},"The Netherlands Cancer Institute",{"name":110,"class":6},"A.O.U. Città della Salute e della Scienza - Molinette Hospital",{"name":112,"class":6},"University Medical Centre Ljubljana","100598002","tumor-rupture-during-robotic-partial-nephrectomy-100598002",false,"NCT07065825","Tumor Rupture During Robotic Partial Nephrectomy","A Retro-Prospective Observational Study on Causes, Characteristics, Intraoperative Management and Impact on Prognosis","RUPTURE","Inclusion Criteria:\n\n* Patients who experienced tumor rupture during RAPN (referred to an unintended breach of the tumor capsule with or without spillage of malignant tissue during tumor resection)\n* Patients who provide informed consent to participate\n* Patients from 18 to 80 years of age.\n\nExclusion Criteria:\n\n* Patients undergoing radical nephrectomy or other nephron-sparing procedures.\n* Patients undergoing partial nephrectomy with other approaches (open, pure laparoscopic)\n* Patients with multiple ipsilateral tumors\n* Patients diagnosed with genetic abnormalities that increase the likelihood of developing renal cell carcinoma.\n* Patients who deny consent.","ALL","18 Years","80 Years",{"count":125,"type":126},100,"ESTIMATED","5 Years","OBSERVATIONAL","The RUPTURE Project is a multi-center observational study aiming to understand tumor rupture during robotic partial nephrectomy (RAPN), a minimally invasive surgery used to treat kidney tumors. Tumor rupture-an unintended break of the tumor capsule during surgery-occurs in about 10-15% of cases but is poorly studied. This event may increase the risk of cancer recurrence or spread, but its true impact is still unclear.\n\nThe study includes adult patients who experienced a tumor rupture during RAPN. Researchers will collect data on patient and tumor characteristics, surgical techniques, how the rupture occurred and was managed, and long-term outcomes. Follow-up visits will monitor for recurrence, metastases, and survival for up to five years. No experimental treatments or extra procedures are involved; only standard care is followed.\n\nBy analyzing at least 100 cases from various hospitals, the study hopes to clarify whether tumor rupture affects prognosis and to identify risk factors and best practices for managing it. This could help improve patient safety, surgical strategies, and future clinical guidelines. All data are handled confidentially, and participation is voluntary.",[131,132],"Kidney Cancer","Renal Neoplasms",[134,135,136,137,138,139,140,141,21,17],"robotic","robotic surgery","partial nephrectomy","tumor rupture","tumour rupture","tumor resection","kidney cancer","small renal mass","NOT_YET_RECRUITING","2025-07-11",{"date":145,"type":146},"2025-07-15","ACTUAL",{"date":148,"type":126},"2025-09",{"date":150,"type":126},"2030-12",{"name":5,"class":6},1]